PMGC Holdings shares surge 24.38% after-hours following 40% acquisition stake in ELAB.

PMGC Holdings surged 24.38% in after-hours trading following a reported 40% acquisition highlighted in BioPharmCatalyst’s daily updates. The move aligns with the news event, which directly references PMGC as a key player in the biotech sector. While Sangamo Therapeutics’ private placement was noted, it pertains to a separate entity and does not influence PMGC’s price action. The acquisition news suggests a strategic expansion or restructuring, likely boosting investor confidence in the company’s growth prospects.